XML 125 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Schedule of Concentration (Details)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Janssen | Accounts Receivable | Credit Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage 29.00% 27.00% 31.00%
Janssen | Revenues Net | Customer Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage 28.00% 29.00% 33.00%
Biogen | Revenues Net | Customer Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage 17.00% 10.00%  
Cardinal Health | Accounts Receivable | Credit Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage 12.00%    
Cardinal Health | Revenues Net | Customer Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage   13.00%  
AmerisourceBergen | Accounts Receivable | Credit Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage 10.00%    
Acorda | Accounts Receivable | Credit Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage   15.00% 14.00%
Acorda | Revenues Net | Customer Concentration Risk      
Revenue Initial Application Period Cumulative Effect Transition [Line Items]      
Concentration risk percentage   10.00% 13.00%